9291 targeted drug, most commonly known commercially as Oseltinib, is a very important drug for EGFR mutations in non-small cell lung cancer lung adenocarcinoma. If EGFR mutation, resistance to 1st generation chemotherapy drugs, TM790 mutation, resistance to 1st generation targeted therapy drugs, such as ERSA, Troche, etc., will be used, which is also known as 9291. 9291, also known as Ostinib, is a specific targeted therapy drug used for lung cancer EGFR mutation after resistance to 1st generation drugs, resulting in TM790 mutation. The specific targeted therapy drug.